With over 50% of all non-small cell lung cancer (NSCLC) patients diagnosed at
the advanced stages of the disease, and 95% of all small-cell lung cancer
(SCLC) patients unsuitable for surgical resection, drug therapy plays a vital
role in the management of lung cancer. Such high level of unmet need ensures
the lung cancer market is an attractive commercial opportunity for new drug
development.
Lung Cancer Therapeutics Market & Pipeline Analysis supports the process of
successful product development and commercialization within the
pharmaceutical/biopharmaceutical lung cancer market by addressing the
following key areas:
Epidemiology of lung cancer
Current lung cancer treatments
Analysis of current lung cancer therapeutics
Unmet needs within the lung cancer market
Research and development (R&D) approaches towards lung cancer
Pipeline analysis of key lung cancer candidates
Forecast sales of key pipeline lung cancer candidates
The report also analyzes the market status and potential for the following key lung cancer therapies:
Sanofi-Aventis' Taxotere (docetaxel)
Eli-Lilly' s Gemzar (gemcitabine)
Eli-Lilly' s Alimta (pemetrexed)
GlaxoSmithKline' s Hycamtin (topotecan) (SCLC therapeutic)
OSI Pharmaceuticals/Roche' s Tarceva (erlotinib)
AstraZeneca' s Iressa (gefitinib)
Roche' s Avastin (bevazicumab)
and the market potential for the following key late-clinical stage
developmental candidates:
Opaxio
Erbitux (line extensions)
Zactima
Picoplatin
This in-depth, quality report delivers:
An assessment of the lung market potential, including identification of
unmet needs, commercial opportunities, and key trends in R&D
Analysis of the lung cancer pipeline with in-depth clinical and commercial
assessment of key Phase III candidates
Seven major pharmaceutical market sales forecasts to 2015 for key pipeline
candidates incorporating product events
Report highlights include:
Arrowhead has identified 70 drugs in the late-stage lung cancer pipeline.
Collectively, key late-phase products have a forecast sales potential of up to
$5651m by 2015 in the seven major pharmaceutical markets.
Molecular targeted therapies (MTTs) are the focus of R&D in lung cancer.
Of the MTTs in late-phase development, Erbitux (cetuximab; ImClone
/Bristol-Myers Squibb/Merck KGaA) is forecast to achieve the highest level of
sales, with $1000m by 2015.
Arrowhead forecasts AstraZeneca' s Iressa (gefitinib) will overcome its
disappointing start in the NSCLC arena following positive results of two
recent Phase III trials. Iressa will go on to compete well with Roche' s
Avastin and OSI Pharma/Roche' s Tarceva (erlotinib).
Purchasing this report will enable you to:
Assess opportunities and risks influencing R&D in lung cancer, unmet needs
in the treatment of the disease, and trends in current development
Identify key lung cancer products in late-phase development based on sales
forecasts to 2015 to maximize your product' s commercial potential
Gain an impartial perspective of the strategies used between competing
companies involved in the lung cancer pipeline to enhance your product' s
performance
Methodology
Cancer Therapeutics Market & Pipeline Analysis is based on both primary and
secondary research. Primary research consists of interviews with leading lung
cancer key opinion leaders. Secondary research is obtained from company annual
reports and web sites, SEC filings, industry publications, on-line journals,
patient advocacy groups and industry conference publications.
Arrowhead interviewed the following key opinion leader during the research of
Cancer Therapeutics Market & Pipeline Analysis.
Dr. Bertrand Mennecier. Medical Oncologist. Hopitaux Universitaires
de Strasbourg, France
Table of Contents
1. EXECUTIVE SUMMARY
1.1 Scope of Lung Cancer Therapeutics: Market Trends and R&D Insights
1.2 Methodology of Lung Cancer Therapeutics: Market Trends and R&D Insights
1.3 Lung Cancer Epidemiology Trends
1.4 Current Therapeutic Treatments of Lung Cancer
1.5 Unmet Needs of Lung Cancer
1.6 Research and Development (R&D) Trends
1.7 Pipeline Analysis
2. LUNG CANCER: DISEASE BACKGROUND
2.1 An Introduction to Lung Cancer
2.2 An Overview of Non Small Cell Lung Cancer (NSCLC)
2.2.1 Squamous Cell Carcinoma
2.2.2 Adenocarcinoma
2.3 Large Cell Carcinoma
2.4 Staging of NSCLC
2.5 Small Cell Lung Cancer (SCLC)
2.6 Staging of SCLC
2.7 Lung Cancer Risk Factors
2.7.1 Smoking
2.7.2 Radon Gas
2.7.3 Asbestos
2.7.4 Personal or Family History of Lung Cancer
2.7.5 Age
2.8 Lung Cancer Symptoms
2.9 Diagnosis of Lung Cancer
2.10 Prognosis of Lung Cancer
3. EPIDEMIOLOGICAL AND FINANCIAL IMPACT OF CANCER
3.1 Epidemiology of Lung Cancer in the Seven Major Markets
3.1.1 Obama' s Family Smoking and Tobacco Control Act: How will this Influence the Lung Cancer Market?
3.2 The Financial Impact of Lung Cancer
3.3 Would a Lung Cancer Screening Program Impact Patient Survivorship and
Reduce the Financial Cost of the Disease?
4. CURRENT LUNG CANCER MANAGEMENT CONTROVERSIES
4.1 An Introduction to the Management of Lung Cancer
4.2 An Overview to the Surgical Resection of Lung Cancer
4.3 An Overview of Radiation Therapy for Lung Cancer
4.4 An Overview of Chemotherapy for Lung Cancer
4.4.1 Overview of the Chemotherapeutic Management of NSCLC
4.4.2 Overview of the Chemotherapeutic Management of SCLC
4.5 First-Line Cytotoxic Management of Lung Cancer
4.5.1 Sanofi-Aventis' Taxotere (docetaxol)
4.5.2 Eli-Lilly' s Gemzar (gemcitabine)
4.5.3 Eli Lilly' s Alimta (pemetrexed)
4.6 Second- and Third-Line Cytotoxic Management of Lung Cancer
4.6.1 Sanofi-Aventis' Taxotere (docetaxel)
4.6.2 Eli Lilly' s Alimta (pemetrexed)
4.6.3 GlaxoSmithKline' s Hycamtin (topotecan)
4.7 Molecular Targeted Therapies (MTTs) Used in the Management of NSCLC
4.7.1 Roche' s Avastin (bevacizumab)
4.7.2 OSI Pharmaceuticals/ Roche' s Tarceva (erlotinib)
4.7.3 AstraZeneca' s Iressa (gefitinib)
4.8 Neo-adjuvant and Adjuvant Lung Cancer Chemotherapy
4.8.1 Adjuvant Lung Cancer Chemotherapy
4.8.2 Neo-adjuvant Lung Cancer Chemotherapy
5. ANALYSIS OF THE LUNG CANCER THERAPEUTICS MARKET
5.1 First-Line Therapies
5.2 Key Branded Cytotoxic Therapies
5.3 SWOT Analysis: Taxotere
5.4 SWOT Analysis: Alimta
5.5 SWOT Analysis: Gemzar
5.6 SWOT Analysis: Hycamtin
5.7 Key Molecular-Targeted Therapies (MTTs)
5.7.1 Avastin
5.7.1.1 SWOT Analysis: Avastin
5.7.2 Tarceva
5.7.2.1 SWOT Analysis: Tarceva
5.7.3 Iressa
5.7.3.1 SWOT Analysis: Iressa
6. UNMET NEEDS IN THE LUNG CANCER THERAPEUTIC MARKET
6.1 Unmet Needs in the Lung Cancer Market
6.2 Five-year Survival Rates Remain Static
6.3 Extensive-Stage SCLC Specific Agent
6.4 First-line Agents that Prevent Disease Relapse
6.5 First-line Agents with Favorable Toxicity Profiles
6.6 Elderly Lung Cancer Patients are Underserved
6.7 Effective Second-Line Agents
6.8 Bronchioalveolar Carcinoma Patients are Underserved
6.9 Stage IIIA Specific Agent
6.10 Development of a Cost-Effective Lung Cancer Screening Program
6.11 Development of a Chemo-Preventative
7. LUNG CANCER RESEARCH AND DEVELOPMENT (R&D) TRENDS
7.1 An Introduction to Oncology Clinical Trials
7.2 Issues Surrounding the Design of Lung Cancer Clinical Trials
7.2.1 Patient Selection
7.2.2 Trial Duration
7.2.3 Trial Comparator Drug Choice
7.2.4 Adjuvant and Neo-adjuvant Trial Design
7.3 An Introduction to Oncology Clinical Trial Endpoints
7.3.1 Survival Rates
7.3.2 Tumor Response Rates
7.3.3 Time to Tumor Progression
7.3.4 Quality of Life
7.3.5 Adverse Effects
7.3.6 Oncology Vaccine Endpoints
7.4 Emerging Lung Cancer Biomarkers May Aid R&D Direction
7.4.1 NSCLC Biomarkers
7.4.2 SCLC Biomarkers
8. LUNG CANCER PIPELINE ANALYSIS
8.1 Introduction to the Lung Cancer Therapeutics Pipeline
8.2 ImClone/Bristol-Myers Squibb/Merck KGaA' s Erbitux (cetuximab)
